Treatment of acute and chronic traumatic brain injury (TBI) is the topic of Arrowhead’s Annual Traumatic Brain Injury Conference on March 7 in Washington, D.C.. Representatives from the government, military, biopharmaceutical industry and academia will be on-hand to discuss TBI research and development.
The overall goal is to realize pharmaceutical management of TBI, even though past clinical trials for new therapies have not met with success. Even so, the U.S. Congress and Department of Defense have a renewed interest in improving treatment options for TBI patients. As it stands now, treatment of TBI is an important unmet medical need.
TBI is a major cause of death and disability worldwide, and mild TBI is the most common injury related to combat. Next to spinal cord injury, TBI is responsible for almost 25 percent of combat casualties. Topics for next month’s DC conference include:
- Post-acute and chronic neurorehabilitation
- Acute TBI
- Halting secondary injury in TBI
- Translating TBI animal results to the clinic
- Proper diagnosis for TBI
- The drug delivery challenges faced by therapy developers
Traumatic brain injuries present life-long challenges to victims and their families. In the United States alone, approximately 1.7 million people sustain a TBI each year. Over 30 percent of injury-related deaths report TBI as a contributing factor.
If you or a loved one suffers from TBI, a Washington, D.C. traumatic brain injury lawyer can help you receive compensation for your injury. Contact Roger C. Johnson, a Washington, D.C. traumatic brain injury attorney at Koonz, McKenney, Johnson, DePaolis & Lightfoot.